Drug Type: Protein Biologic
Mechanism Type: Neuroprotection
Mechanism: sNN0029 is a formulation of vascular endothelial growth factor (VEGF) protein that is suitable for administration into the central nervous system. The drug will be delivered via intracerebroventricular infusion. Multiple studies have shown that VEGF expression is impaired in ALS, and that VEGF treatment ameliorates disease in ALS mouse models.
U.S. Status for ALS: Discontinued
 Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Storkebaum, E et al. Nat Neurosci. 2005 Jan;8(1):85-92.
 An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis. ClinicalTrials.gov, 26 Jan 2016. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT01384162.
Last updated June 21st, 2017